Small Bowel Transit Time in Clostridium Difficile Colitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01309750|
Recruitment Status : Terminated (logistics)
First Posted : March 7, 2011
Last Update Posted : January 25, 2017
|Condition or disease||Intervention/treatment|
|Clostridium Difficile Colitis||Radiation: Small Bowel Transit Study|
|Study Type :||Observational|
|Actual Enrollment :||1 participants|
|Official Title:||Small Bowel Transit Time in Clostridium Difficile Colitis|
|Study Start Date :||April 2011|
|Actual Primary Completion Date :||February 2012|
|Actual Study Completion Date :||February 2012|
Patients with Clostridium difficile colitis admitted to the intensive care unit will be the study group.
Radiation: Small Bowel Transit Study
Patients that are enrolled and consented in the study will be given 300ml of water containing 5 millicurie (mCi) of technetium-99m (Tc-99m) diethylenetriamine pentaacetate (DTPA). This nuclear tracer/water mix will either be drank orally or placed down a nasogastric tube to begin the study. The patient will have to have nothing else to eat or drink for the duration of the study. The patients will have a nuclear scan performed at 2, 4, and 6 hours after ingestion of the nuclear tracer.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01309750
|United States, Michigan|
|William Beaumont Hospital|
|Royal Oak, Michigan, United States, 48073|
|Principal Investigator:||Marc B Grodsky||William Beaumont Hospitals|